DBV Technologies (DBV) Q1 2025 earnings summary

Executive summary

• Focused on advancing Viaskin Peanut patch for peanut allergy in children, with parallel regulatory strategies in the US and EU for different age groups.

• Ongoing pivotal Phase 3 VITESSE trial in children 4–7 years; topline results expected Q4 2025.

• No product revenue generated; company remains in clinical stage, preparing for potential launches in the US and EU if approved.

• Regulatory alignment with FDA for Accelerated Approval pathway in toddlers 1–3 years; BLA submission planned with new safety data.

• Recent $125.5M financing extends cash runway into June 2026, with potential for further proceeds if warrants are exercised.

Financial highlights

• Net loss for Q1 2025 was $27.1M, slightly improved from $27.3M in Q1 2024.

• Operating expenses decreased to $27.4M from $30.0M year-over-year, primarily due to lower general & administrative costs.

• Cash and cash equivalents were $13.0M at March 31, 2025, down from $32.5M at year-end 2024, mainly due to $19.7M used in operating activities.

• Operating income decreased to $0.75M, mainly due to lower research tax credits.

• Net cash used in operating activities was $19.7M, a 43% improvement from Q1 2024.

Outlook and guidance

• Cash runway expected into June 2026 based on current operations and recent financing.

• BLA submission for Viaskin Peanut in 4–7 years planned for H1 2026, potentially accelerating launch by one year.

• Focus remains on advancing Viaskin Peanut Patch through BLA submission and potential US commercial launch.

• Additional warrant exercises could extend financial visibility into 2028 and through potential US commercialization.